CR20140395A - Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilamina - Google Patents

Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilamina

Info

Publication number
CR20140395A
CR20140395A CR20140395A CR20140395A CR20140395A CR 20140395 A CR20140395 A CR 20140395A CR 20140395 A CR20140395 A CR 20140395A CR 20140395 A CR20140395 A CR 20140395A CR 20140395 A CR20140395 A CR 20140395A
Authority
CR
Costa Rica
Prior art keywords
processes
preparation
metansulfoniletilamine
metoxifenil
etoxi
Prior art date
Application number
CR20140395A
Other languages
English (en)
Inventor
Jasti Venkateswaralu
Chinnapillai Rajendiran
Nallamaddi Ravikumar Reddy
Terrence Joseph Connolly
Alexander L Ruchelman
Jeffrey Eckert
Anthony Joseph Frank
Original Assignee
Celgene Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47755073&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20140395(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Celgene Corp filed Critical Celgene Corp
Publication of CR20140395A publication Critical patent/CR20140395A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C313/00—Sulfinic acids; Sulfenic acids; Halides, esters or anhydrides thereof; Amides of sulfinic or sulfenic acids, i.e. compounds having singly-bound oxygen atoms of sulfinic or sulfenic groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C313/02—Sulfinic acids; Derivatives thereof
    • C07C313/06—Sulfinamides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C315/00—Preparation of sulfones; Preparation of sulfoxides
    • C07C315/04—Preparation of sulfones; Preparation of sulfoxides by reactions not involving the formation of sulfone or sulfoxide groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/24—Sulfones; Sulfoxides having sulfone or sulfoxide groups and doubly-bound oxygen atoms bound to the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se proveen nuevos procesos para la preparación de intermediarios de aminosulfona para la síntesis de 2-[1-(3-etoxi-4-metoxifenil)-2-metilsulfonil-etil]-4-acetilaminoisoindolino-1,3-diona, que es útil para prevenir o tratar enfermedades o condiciones relacionadas con un nivel o actividad anormalmente alto de TNF-?. Además, en el presente documento se proveen procesos para la producción comercial de (S)-1-(3-etoxi-4-metoxifenil)-2-metansulfonil-etilamina.
CR20140395A 2012-02-21 2014-08-21 Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilamina CR20140395A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261601226P 2012-02-21 2012-02-21
PCT/US2013/026780 WO2013126360A2 (en) 2012-02-21 2013-02-20 Processes for the preparation of (s)-1-(3-ethoxy-4methoxyphenyl)-2-methanesulfonylethylamine

Publications (1)

Publication Number Publication Date
CR20140395A true CR20140395A (es) 2014-11-17

Family

ID=47755073

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20140395A CR20140395A (es) 2012-02-21 2014-08-21 Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilamina

Country Status (36)

Country Link
US (3) US9187417B2 (es)
EP (4) EP3312156B1 (es)
JP (1) JP2015509496A (es)
KR (1) KR101993248B1 (es)
CN (3) CN104245668B (es)
AR (2) AR090100A1 (es)
AU (1) AU2013203283B2 (es)
BR (3) BR122021020046B1 (es)
CA (1) CA2864517A1 (es)
CO (1) CO7061071A2 (es)
CR (1) CR20140395A (es)
CY (2) CY1121833T1 (es)
DK (2) DK3378850T3 (es)
ES (4) ES2773686T3 (es)
HK (1) HK1205501A1 (es)
HR (2) HRP20191249T1 (es)
HU (2) HUE044192T2 (es)
IL (3) IL234135A (es)
IN (1) IN2014DN06740A (es)
LT (2) LT3378850T (es)
MX (2) MX344190B (es)
MY (1) MY168296A (es)
NI (1) NI201400093A (es)
NZ (1) NZ628028A (es)
PH (1) PH12014501865B1 (es)
PL (2) PL3378850T3 (es)
PT (2) PT3312156T (es)
RS (2) RS59071B1 (es)
RU (1) RU2632875C2 (es)
SG (1) SG11201405035XA (es)
SI (2) SI3378850T1 (es)
TR (1) TR201910430T4 (es)
TW (1) TW201336815A (es)
UA (1) UA116773C2 (es)
WO (1) WO2013126360A2 (es)
ZA (1) ZA201405892B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
EP3539539A1 (en) 2013-06-17 2019-09-18 Celgene Corporation Tablet formulations of (+)-2-[1 -(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione
IN2014MU01283A (es) 2014-04-04 2015-10-09 Cadila Healthcare Ltd
WO2015173792A1 (en) 2014-05-11 2015-11-19 Mapi Pharma Ltd. Amorphous form of apremilast
EP2949645A1 (en) 2014-05-28 2015-12-02 LEK Pharmaceuticals d.d. Processes for the preparation of ß-aminosulfone compounds
CN105622380B (zh) * 2014-10-29 2020-06-30 南京安源生物医药科技有限公司 一种阿普斯特的制备方法及其中间体
CN104447445B (zh) * 2014-12-05 2016-07-06 新发药业有限公司 一种合成阿普斯特中间体的制备方法
CN104744323B (zh) * 2015-03-11 2016-08-31 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成工艺
CN104761474B (zh) * 2015-03-11 2016-11-30 中山奕安泰医药科技有限公司 一种阿普斯特手性胺中间体的合成方法
CN104803897A (zh) * 2015-04-23 2015-07-29 中山奕安泰医药科技有限公司 一种阿普斯特中间体的合成工艺
WO2016174685A1 (en) 2015-04-27 2016-11-03 Mylan Laboratories Limited Process for the enantiomeric resolution of apremilast intermediates
WO2016199031A1 (en) * 2015-06-09 2016-12-15 Dr. Reddy’S Laboratories Limited Process for preparation of apremilast and its intermediates
EP3106457A1 (en) 2015-06-15 2016-12-21 LEK Pharmaceuticals d.d. A novel synthetic pathway towards apremilast
EP3144393A1 (en) 2015-09-18 2017-03-22 LEK Pharmaceuticals d.d. A synthetic pathway towards apremilast
WO2017059040A1 (en) 2015-09-29 2017-04-06 Pliva Hrvatska D.O.O. Processes for the preparation of apremilast and intermediates thereof
WO2017085568A1 (en) * 2015-11-19 2017-05-26 Alembic Pharmaceuticals Limited An improved process and novel polymorphic form of apremilast
CN105461602B (zh) * 2015-11-27 2018-01-02 东华大学 手性S或R‑3‑乙氧基‑4‑甲氧基‑α‑[(甲磺酰基)甲基]苯甲醇的制备方法
CN105330586B (zh) * 2015-11-27 2017-12-22 东华大学 一种阿普斯特的制备方法
WO2017094031A2 (en) * 2015-12-04 2017-06-08 Sun Pharmaceutical Industries Limited Novel process for preparation of apremilast
CN106866475B (zh) * 2015-12-11 2018-03-30 北大方正集团有限公司 一种阿普斯特中间体及其制备方法
US10774041B2 (en) 2016-04-15 2020-09-15 Davuluri Ramamohan Rao Process for the preparation of apremilast
US10196355B2 (en) 2016-06-20 2019-02-05 Johnson Matthey Public Limited Company Forms of apremilast
CN106543050B (zh) * 2016-09-28 2018-04-10 中南大学湘雅医院 一种阿普斯特中间体的合成工艺
WO2018061034A1 (en) * 2016-09-30 2018-04-05 Sun Pharmaceutical Industries Limited Novel process for the preparation of 1-(3-ethoxy-4-methoxy-phenyl)-2-methylsulfonyl-ethanamine
US11000888B2 (en) 2016-11-10 2021-05-11 Sms Group Gmbh Method for producing a metal strip in a cast-rolling installation
CN107445875A (zh) * 2017-03-22 2017-12-08 陕西科技大学 一种用于制备阿普斯特的高纯度中间体的手性拆分方法
EP3606907B1 (en) 2017-04-04 2021-01-20 Quimica Sintetica, S.A. Racemic beta-aminosulfone compounds
SI3606908T1 (sl) 2017-04-04 2020-10-30 Quimica Sintetica, S.A. Delitev racemičnih beta-aminosulfonskih spojin
CN107941945B (zh) * 2017-11-23 2020-12-22 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲腈的检测方法
CN108008035B (zh) * 2017-11-23 2020-07-07 中山奕安泰医药科技有限公司 3-乙氧基-4-甲氧基苯甲醛纯度的检测方法
CN107976501B (zh) * 2017-11-23 2020-08-25 中山奕安泰医药科技有限公司 一种1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107966509B (zh) * 2017-11-23 2020-06-23 中山奕安泰医药科技有限公司 一种(s)-1-(3-乙氧基-4-甲氧基苯基)-2-(甲基磺酰基)乙胺的检测方法
CN107827722B (zh) * 2017-11-23 2021-02-19 中山奕安泰医药科技有限公司 一种3-乙氧基-4-甲氧基苯甲醛的合成方法
CN108084066A (zh) * 2017-12-12 2018-05-29 中山大学 一种阿普斯特及对映异构体的合成方法
JP6673614B1 (ja) * 2018-10-16 2020-03-25 東芝エレベータ株式会社 防音装置
CN113896674B (zh) * 2021-09-01 2023-10-27 深圳华中科技大学研究院 一种阿普斯特的合成方法
CN116332954A (zh) 2021-12-21 2023-06-27 赣州和美药业股份有限公司 噻吩衍生物的制备
CN115850129B (zh) * 2023-02-28 2023-05-16 凯莱英生命科学技术(天津)有限公司 （s）-1-(3-乙氧基-4-甲氧基苯基)-2-（甲磺酰基）乙胺的制备方法

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1261455A (en) * 1969-03-06 1972-01-26 Burroughs Wellcome Co Improvements in or relating to substituted acrylonitriles
US3878252A (en) * 1970-09-24 1975-04-15 Burroughs Wellcome Co Ring substituted beta-hydroxy-phenyethylmethyl sulphone or sulphoxide
DE2051871A1 (en) * 1969-05-16 1971-11-18 The Wellcome Foundation Ltd., London Beta-amino-alpha-aryloxymethylacrylonitrile - and 2,4-diamino-5-benzylpyrimidine derivs. useful as antibacterial agents
EE9800299A (et) 1996-03-22 1999-06-15 The Du Pont Merck Pharmaceutical Company R-a-propüül-piperonüülamiini ja selle analoogide uudne asümmeetriline sünteesimine
US6020358A (en) 1998-10-30 2000-02-01 Celgene Corporation Substituted phenethylsulfones and method of reducing TNFα levels
US6962940B2 (en) 2002-03-20 2005-11-08 Celgene Corporation (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof
US7893101B2 (en) 2002-03-20 2011-02-22 Celgene Corporation Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof
ATE449081T1 (de) 2002-12-30 2009-12-15 Celgene Corp Fluoralkoxy-substituierte 1, 3-dihydro-isoindolyl-verbindungen und ihre pharmazeutischen verwendungen
US7208526B2 (en) 2005-05-20 2007-04-24 Hoffmann-La Roche Inc. Styrylsulfonamides
WO2009094528A1 (en) * 2008-01-25 2009-07-30 High Point Pharmaceuticals, Llc TRICYCLIC COMPOUNDS AS MODULATORS OF TNF-α SYNTHESIS AND AS PDE4 INHIBITORS
EP2334639B1 (en) * 2008-09-10 2013-01-23 Celgene Corporation Processes for the preparation of aminosulfone compounds
PT2443089E (pt) * 2009-06-18 2014-06-23 Concert Pharmaceuticals Inc Derivados de isoindolina-1,3-diona deuterados como inibidores de pde4 e tnf-alfa
RU2557236C2 (ru) 2009-10-09 2015-07-20 Селджин Корпорейшн Способ получения соединений 2-(1-фенилэтил)изоиндолин-1-она
US9045417B2 (en) 2011-01-14 2015-06-02 Celgene Corporation Isotopologues of isoindole derivatives
US9126906B2 (en) * 2012-02-21 2015-09-08 Celgene Corporation Asymmetric synthetic processes for the preparation of aminosulfone compounds
AR090100A1 (es) * 2012-02-21 2014-10-22 Celgene Corp Procesos para la preparacion de la (s)-1-(3-etoxi-4-metoxifenil)-2-metanosulfoniletilamina

Also Published As

Publication number Publication date
ES2735801T3 (es) 2019-12-20
KR20140126389A (ko) 2014-10-30
EP3312156A1 (en) 2018-04-25
TR201910430T4 (tr) 2019-08-21
MY168296A (en) 2018-10-23
PL3378850T3 (pl) 2020-07-27
CN104245668B (zh) 2017-05-17
LT3312156T (lt) 2019-08-12
MX2014010002A (es) 2014-09-08
PT3312156T (pt) 2019-07-19
RS60036B1 (sr) 2020-04-30
EP3378850B8 (en) 2020-03-04
BR112014020444B1 (pt) 2021-12-07
SG11201405035XA (en) 2014-09-26
ES2971710T3 (es) 2024-06-06
IL252459B (en) 2020-03-31
PT3378850T (pt) 2020-03-06
US9688623B2 (en) 2017-06-27
PH12014501865A1 (en) 2014-11-17
EP3312156B1 (en) 2019-06-05
EP2817288A2 (en) 2014-12-31
EP3378850B1 (en) 2020-01-08
DK3378850T3 (da) 2020-03-16
CY1122799T1 (el) 2021-05-05
RU2632875C2 (ru) 2017-10-11
US20160031808A1 (en) 2016-02-04
AR117963A2 (es) 2021-09-08
CN107033042A (zh) 2017-08-11
HK1205501A1 (en) 2015-12-18
CN104245668A (zh) 2014-12-24
AU2013203283B2 (en) 2015-11-26
WO2013126360A2 (en) 2013-08-29
CN112812044A (zh) 2021-05-18
KR101993248B1 (ko) 2019-06-26
IL234135A (en) 2017-06-29
IN2014DN06740A (es) 2015-05-22
BR122021020040B1 (pt) 2022-05-31
RU2014138037A (ru) 2016-04-10
EP3702347A1 (en) 2020-09-02
UA116773C2 (uk) 2018-05-10
EP3378850A1 (en) 2018-09-26
CN112812044B (zh) 2023-05-30
JP2015509496A (ja) 2015-03-30
BR122021020046B1 (pt) 2022-05-31
CA2864517A1 (en) 2013-08-29
HRP20200245T1 (hr) 2020-05-15
IL273050A (en) 2020-04-30
MX350731B (es) 2017-09-15
CO7061071A2 (es) 2014-09-19
ES2773686T3 (es) 2020-07-14
US20170129852A1 (en) 2017-05-11
CY1121833T1 (el) 2020-10-14
SI3378850T1 (sl) 2020-07-31
NI201400093A (es) 2016-11-30
HRP20191249T1 (hr) 2019-10-18
DK3312156T3 (da) 2019-07-22
HUE048412T2 (hu) 2020-07-28
MX344190B (es) 2016-12-08
RS59071B1 (sr) 2019-09-30
ZA201405892B (en) 2015-11-25
LT3378850T (lt) 2020-04-10
PL3312156T3 (pl) 2019-10-31
SI3312156T1 (sl) 2019-09-30
US20130217918A1 (en) 2013-08-22
AU2013203283A1 (en) 2013-09-05
US9187417B2 (en) 2015-11-17
ES2675168T3 (es) 2018-07-09
US9586897B2 (en) 2017-03-07
PH12014501865B1 (en) 2014-11-17
IL252459A0 (en) 2017-07-31
NZ628028A (en) 2016-03-31
HUE044192T2 (hu) 2019-10-28
BR112014020444A2 (pt) 2020-10-27
EP2817288B1 (en) 2018-05-30
AR090100A1 (es) 2014-10-22
EP3702347B1 (en) 2023-11-08
TW201336815A (zh) 2013-09-16
WO2013126360A3 (en) 2013-10-31

Similar Documents

Publication Publication Date Title
CR20140395A (es) Procesos para la preparación de (s)-1-(-3-etoxi-4-metoxifenil)-2-metansulfoniletilamina
UY34216A (es) Nuevos compuestos que inhiben la actividad de la Lp-PLA2
ECSP13012993A (es) Inhibidores de nampt y rock
GT201400034A (es) Compuestos y composiciones como inhibidores de la quinasa c-kit
CL2014000746A1 (es) Compuestos derivados de 3-pirimidin-4-il-oxazolidin-2-ona y sus sales, como inhibidores de las proteinas idh mutantes; composicion farmaceutica que los comprende, utiles para el tratamiento de trastornos de la proliferacion celular tal como el cancer.
UY34445A (es) Nuevos compuestos inhibidores de la fosfodiesterasa del tipo 10a
DOP2017000013A (es) Procedimiento de preparación de 5-fluoro-1h-pirazolopiridinas sustituidas
GT201300258A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
DOP2012000238A (es) Compuestos de para la inhibición de inmunoproteasomas
MX358128B (es) Compuestos y métodos para la modulación de quinasas e indicaciones para los mismos.
GT201400063A (es) Benzilindazoles sustituidos para uso como inhibidores de la quinasa bub1 en el tratamiento de enfermedades hiperproliferativas
UY33627A (es) Compuestos para tratar enfermedades neurodegenerativas
CR20130550A (es) Ciclopropilaminas como inhibidores de desmetilasa 1 específica de lisina
DOP2014000027A (es) Polimorfos de inhibidores de cinasas
ECSP088961A (es) Nuevos herbicidas
UY34336A (es) Derivados 5-fluoro pirimidina disustituidos que contienen un grupo sulfoximina
GT201400090A (es) 2-tiopirimidinonas
UY34108A (es) ?proceso para la fabricación de sustratos revestidos?.
CL2014002661A1 (es) Compuestos derivados de tienopirimidina o sus sales, como inhibidores de la alk quinasa; su proceso de preparacion; composicion farmaceutica que los comprende, util para el tratamiento del cancer.
UY34615A (es) Nuevos compuestos útiles para el tratamiento de enfermedades degenerativas e inflamatorias.
DOP2016000120A (es) Nuevos inhibidores de dgat2
MX349254B (es) Compuestos para el tratamiento del sindrome metabolico.
CL2013000310A1 (es) Compuestos derivados de tetrahidrofuranilo disustituidos y sus sales, como antagonistas del receptor b1 de bradiquinina; medicamento que contiene a dichos compuestos; su procedimiento de preparacion, util para el tratamiento agudo o profilactico de dolores agudos, osteoartritis, asma, alergias, entre otras enfermedades.
DOP2012000260A (es) Uso de nuevos inhibidores de pan–cdk para tratar tumores
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.